Home Cart Sign in  
Chemical Structure| 1393466-87-9 Chemical Structure| 1393466-87-9

Structure of PLX8394
CAS No.: 1393466-87-9

Chemical Structure| 1393466-87-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PLX8394 is a potent and selective inhibitor of BRaf, with an IC50 of approximately 5 nM for BRAFV600E.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PLX8394

CAS No. :1393466-87-9
Formula : C25H21F3N6O3S
M.W : 542.53
SMILES Code : O=C(C1=C(F)C(NS(=O)(N2CC[C@@H](F)C2)=O)=CC=C1F)C3=CNC4=C3C=C(C=N4)C5=CN=C(C6CC6)N=C5
MDL No. :MFCD29472263
InChI Key :YYACLQUDUDXAPA-MRXNPFEDSA-N
Pubchem ID :90116675

Safety of PLX8394

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PLX8394

MAPK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LIM2405 cells 1 µM 6 hours Both PLX8394 and vemurafenib reduced pMEK and pERK levels Mol Cancer. 2017 Jun 28;16(1):112.
COLO 201 cells 1 µM 6 hours Both PLX8394 and vemurafenib reduced pMEK and pERK levels Mol Cancer. 2017 Jun 28;16(1):112.
SK-MEL-239 cells 39 nM 1 hour PLX8394 inhibited p-ERK in SK-MEL-239 cells with an IC75 of 39 nM Nat Med. 2019 Feb;25(2):284-291.
SK-MEL-239 C4 cells 158 nM 1 hour PLX8394 inhibited p-ERK in SK-MEL-239 C4 cells with an IC75 of 158 nM Nat Med. 2019 Feb;25(2):284-291.
293H (NRAS Q61K) cells 100–300 nM 1 hour PLX8394 significantly reduced the levels of RAS-dependent full-length BRAF/BRAF or BRAF/CRAF dimers and RAS-independent BRAF dimers (p61 BRAF) in 293H (NRAS Q61K) cells with an IC50 of 100–300 nM Nat Med. 2019 Feb;25(2):284-291.
HEK293 cells 1 µM 15 minutes Assess the impact of PLX8394 on BRAF-V600E KinCon reporter dynamics, showing that PLX8394 exposure promotes an immediate closing event. Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31105-31113.
Human Dermal Fibroblasts (HDF) 2 µM 18 hours To evaluate the effect of PLX8394 on the proliferative state of HDF, results showed that PLX8394 did not increase cell proliferation Cell Commun Signal. 2021 Dec 20;19(1):123.
RT3 cells 10 µM 24 hours PLX8394 significantly inhibited TGF-β signaling, reduced phosphorylation of Smad2 and TGF-β receptor II, as well as p38 activity, MMP-1 and MMP-13 synthesis, and decreased laminin-332 accumulation. Oncogene. 2023 Dec;42(49):3633-3647.
HaCaT cells 10 µM 24 hours PLX8394 completely prevented TGF-β-induced Smad2 phosphorylation in both HaCaT and RT3 cells. Oncogene. 2023 Dec;42(49):3633-3647.
HEK293T cells 1 µM 4 hours PLX8394 failed to induce BRAF/RAF1 heterodimers, indicating its inhibitory effect on RAF dimerization Cell Commun Signal. 2023 Jun 14;21(1):136.
A2058 melanoma cells 10 µM 4 hours and 18 hours PLX8394 blocked Smad2 activation in A2058 melanoma cells. Oncogene. 2023 Dec;42(49):3633-3647.
LM-COL-1 cells 1 µM 6 hours PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK Mol Cancer. 2017 Jun 28;16(1):112.
ALA cells 1 µM 6 hours PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK Mol Cancer. 2017 Jun 28;16(1):112.
LS513 cells 1 µM 6 hours PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK Mol Cancer. 2017 Jun 28;16(1):112.
HCT 116 cells 1 µM 6 hours PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK Mol Cancer. 2017 Jun 28;16(1):112.
HEK293 cells 1 nM Assess the impact of PLX8394 on BRAF-N581S KinCon reporter dynamics, showing an immediate closing effect with the lowest dose of PLX8394. Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31105-31113.
LM-COL-1 1 μM 6 h To verify whether CCcould avoid paradoxical activation of the MAPK signaling pathway in LM-COL-1 cells, results showed minimal effect of PLX8394 on pMEK and pERK. Mol Cancer. 2017 Jun 28;16(1):112.
ALA 1 μM 6 h To verify whether PLX8394 could avoid paradoxical activation of the MAPK signaling pathway in ALA cells, results showed minimal effect of PLX8394 on pMEK and pERK. Mol Cancer. 2017 Jun 28;16(1):112.
LS513 1 μM 6 h To verify whether PLX8394 could avoid paradoxical activation of the MAPK signaling pathway in LS513 cells, results showed minimal effect of PLX8394 on pMEK and pERK. Mol Cancer. 2017 Jun 28;16(1):112.
HCT 116 1 μM 6 h To verify whether PLX8394 could avoid paradoxical activation of the MAPK signaling pathway in HCT 116 cells, results showed minimal effect of PLX8394 on pMEK and pERK. Mol Cancer. 2017 Jun 28;16(1):112.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID/SCID mice Human cSCC xenograft model Oral 150 mg/kg Once daily for 18 days PLX8394 significantly suppressed the growth of human cSCC xenograft tumors and reduced collagen degradation in the tumors. Oncogene. 2023 Dec;42(49):3633-3647.
SCID/SCID mice Human cSCC xenograft model Oral gavage 150 mg/kg Once daily for 18 days Significantly inhibits the growth of human cSCC tumors and reduces in vivo collagen degradation Oncogene. 2023 Dec;42(49):3633-3647.
SCID/SCID mice CSCC xenograft model Oral 150 mg/kg Once daily for 18 days PLX8394 significantly suppressed the growth of cSCC xenograft tumors and reduced collagen degradation in tumors, indicating its therapeutic potential for cSCC. Oncogene. 2023 Dec;42(49):3633-3647.
NOD/SCID mice Fibroblastoma model Oral 200 mg/kg Twice a day until the experimental endpoint To evaluate the inhibitory effect of PLX8394 on fibroblastomas induced by BRAF mutants, results showed that PLX8394 significantly inhibited tumor growth Theranostics. 2025 Jan 6;15(5):2035-2051
Nude mice Melanoma xenograft model Oral 50 mg/kg Twice daily, continuous treatment PLX8394 was well tolerated in melanoma xenograft models and effectively inhibited tumor growth at a dose of 50 mg/kg Nat Med. 2019 Feb;25(2):284-291.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02012231 Melanoma|Thyroid Cancer|Colore... More >>ctal Cancer|Non-small Cell Lung Cancer|Cholangiocarcinoma|Histiocytosis|Hairy Cell Leukemia Less << PHASE1 TERMINATED 2025-06-15 Scottsdale Healthcare, Scottsd... More >>ale, Arizona, 85258, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Evergreen Hematology & Oncology, Spokane, Washington, 99218, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.22mL

1.84mL

0.92mL

18.43mL

3.69mL

1.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories